N‐acetylaspartate normalization in bipolar depression after lamotrigine treatment

Bipolar Disorders - Tập 17 Số 4 - Trang 450-457 - 2015
Paul E. Croarkin1, M. Albert Thomas2, John D. Port3, Joshua Baruth4, Doo‐Sup Choi5, Osama A. Abulseoud1, Mark A. Frye1
1Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
2Department of Radiology, Psychiatry, and Biomedical Engineering, Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
3Department of Radiology, Mayo Clinic, Rochester, MN, USA
4University of Louisville School of Medicine, Louisville, Ky. USA
5Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN USA

Tóm tắt

ObjectivesThe aim of the present study was to examine N‐acetylaspartate (NAA), a general marker of neuronal viability, and total NAA (tNAA), the combined signal of NAA and N‐acetylaspartylglutamate, in bipolar depression before and after lamotrigine treatment. Given that NAA is synthesized through direct acetylation of aspartate by acetyl‐coenzyme A‐l‐aspartate‐N‐acetyltransferase, we hypothesized that treatment with lamotrigine would be associated with an increase in NAA level.MethodsPatients with bipolar depression underwent two‐dimensional proton magnetic resonance spectroscopy of the anterior cingulate at baseline (n = 15) and after 12 weeks of lamotrigine treatment (n = 10). A group of age‐matched healthy controls (n = 9) underwent scanning at baseline for comparison.ResultsAt baseline, patients with bipolar depression had significantly lower NAA [mean standard deviation (SD) = 1.13 (0.21); p = 0.02] than controls [mean (SD) = 1.37 (0.27)]. Significant increases in NAA [mean (SD) = 1.39 (0.21); p = 0.01] and tNAA [mean (SD) = 1.61 (0.25); p = 0.02] levels were found after 12 weeks of lamotrigine treatment.ConclusionsThese data suggest an NAA deficit in bipolar depression that is normalized after lamotrigine treatment. Future research is warranted to evaluate whether baseline NAA level is a potential biomarker for identifying lamotrigine response patterns and whether this functional brain change has an associated clinical response.

Từ khóa


Tài liệu tham khảo

10.4088/JCP.v65n0321

10.4088/JCP.8125tx3c

10.1056/NEJMcp1000402

10.1097/00004714-200012000-00004

10.1192/bjp.bp.107.048504

10.4088/JCP.08m04152

10.1016/0006-8993(93)91660-K

10.1111/j.1528-1167.2007.01526.x

10.1017/S1461145712000429

10.1016/j.clinph.2012.05.011

10.1006/exnr.2001.7681

10.1089/neu.2010.1683

10.1038/npp.2012.126

10.1073/pnas.0409184102

10.1046/j.1471-4159.2000.0750453.x

10.1016/j.mehy.2006.02.047

10.1016/j.brainres.2008.06.040

10.1111/j.1749-6632.1996.tb34449.x

10.1001/jamapsychiatry.2013.2437

10.1016/S0006-3223(00)00252-3

10.1177/197140090601900602

10.1007/7854_2011_197

10.1002/nbm.1080

10.1002/mrm.1160

10.1002/jmri.23848

10.1155/2012/179365

10.1016/j.pscychresns.2013.02.008

First MB, 2002, Structured Clinical Interview for DSM‐IV‐TR Axis I Disorders, Research Version, Non‐Patient Edition (SCID‐I/NP)

10.1192/bjp.134.4.382

10.1017/S0033291700035558

10.1016/j.pscychresns.2006.11.003

10.1038/sj.npp.1301387

10.1002/nbm.1026

Yi YH, 2008, Neuroprotection of lamotrigine on hypoxic‐ischemic brain damage in neonatal rats: relations to administration time and doses, Biologics, 2, 339

10.1503/jpn.110097

10.1111/j.1399-5618.2008.00627.x

10.1016/j.biopsych.2010.06.016

10.1016/j.neuropharm.2011.07.036

10.1046/j.1471-4159.2003.01905.x

10.1016/j.pneurobio.2006.12.003

10.1097/01.WCB.0000050066.57184.60

10.1073/pnas.95.22.13290

10.1016/S0006-3223(01)01080-0

10.1016/j.neubiorev.2014.02.008

10.1038/nm.3162

10.1038/sj.npp.1300950

10.1038/npp.2009.191

10.1038/sj.npp.1300520

10.1097/00004850-200303000-00002

10.1016/j.jad.2004.12.008

10.1016/j.jaac.2012.03.009

10.1111/j.1399-5618.2012.01033.x

10.1002/jmri.24510

Pettegrew JW, 2011, Understanding Neuropsychiatric Disorders: Insights from Neuroimaging, 56

Thông tin
Thông tin xuất bản

Bipolar Disorders

Tập 17 Số 4

450-457

Thông tin tác giả